Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association of Benign Prostate Hyperplasia with Polymorphisms in VDR, CYP17, and SRD5A2 Genes among Lebanese Men

  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The aim of the study was to investigate any associations between benign prostate hyperplasia (BPH) and single nucleotide polymorphisms (SNPs) in the VDR gene (FokI, BsmI, ApaI and Taq${\alpha}$I loci) and the CYP17 gene (MspA1I locus), as well as TA repeat polymorphism in SRD5A2 gene among Lebanese men. Materials and Methods: DNA extracted from blood of 68 subjects with confirmed BPH and 79 age-matched controls was subjected to PCR/PCR-restriction fragment length polymorphism analysis. The odds ra=tio (OR) of having a genotype and the relative risk (RR) of developing BPH for having the genotype were calculated and the alleles were designated risk-bearing or protective. Results: Our data indicated that the A and B alleles of the VDR ApaI and BsmI SNPs were highly associated with increased risk of BPH (p=0.0168 and 0.0002, respectively). Moreover, 63% of the controls compared to 43% of the subjects with BPH were homozygous for none of the risk-bearing alleles (p=0.0123) whereas 60% of the controls and 28% of the subjects with BPH were homozygous for two or more protective alleles (p<0.0001). Conclusions: For the first time, our study demonstrated that ApaI and BsmI of the VDR gene are associated with risk of BPH among Lebanese men. Our study also indicated that overall polymorphism profile of all the genes involved in prostate physiology could be a better predictor of BPH risk.

Keywords

References

  1. Anim JT, Kehinde EO, Sheikh MA, et al (2007). Serum prostate specific antigen levels in middle eastern men with subclinical prostatitis. Med Princ Pract, 16, 53-8
  2. Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K (2001). Racial differences in cellular composition of benign prostatic hyperplasia. The Prostate, 49, 243-50. https://doi.org/10.1002/pros.10019
  3. Azzouzi AR, Cochand-Priollet B, Mangin P, et al (2002). Impact of constitutional genetic variation in androgen/oestrogenregulating genes on age-related changes in human prostate. Eur J Endocrinol, 147, 479-84. https://doi.org/10.1530/eje.0.1470479
  4. Bousema JT, Bussemakers MJ, van Houwelingen KP, et al (2000). Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol, 37, 234-8. https://doi.org/10.1159/000020124
  5. Central Intelligence Agency. The World Factbook. https://www.cia.gov (accessed Dec 15, 2013).
  6. Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, Thammavit W (2006). Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev, 7, 136-9.
  7. Chang RT, Kirby R, Challacombe BJ (2012). Is there a link between BPH and prostate cancer? Practitioner, 256, 13-6.
  8. Dwivedi S, Goel A, Natu SM, et al (2011). Diagnostic and prognostic of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev, 12, 1843-8.
  9. Falleti E, Bitetto D, Fabris C, et al (2010). Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol, 16, 3016-24. https://doi.org/10.3748/wjg.v16.i24.3016
  10. Feigelson HS, Coetzee GA, Kolonel LN, Ross PK, Henderson BE (1997). Polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57, 1063-65.
  11. Forrest MS, Edwards SM, Houlston R, et al (2005). Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis, 8, 95-102. https://doi.org/10.1038/sj.pcan.4500785
  12. Gunes S, Bagci H, Sarikaya S, Bilen CY, Kara N (2007). Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. DNA Cell Biol, 26, 873-8. https://doi.org/10.1089/dna.2007.0646
  13. Guo YJ, Shi ZM, Liu JD et al (2012). Meta-analysis of the relation between the VDR gene TaqI polymorphism and genetic susceptibility to prostate cancer in Asian populations. Asian Pac J Cancer Prev, 13, 4441-4. https://doi.org/10.7314/APJCP.2012.13.9.4441
  14. Habuchi T, Suzuki T, Sasaki R, et al (2000a). Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res, 60, 305-8.
  15. Habuchi T, Liqing Z, Suzuki T, et al (2000b). Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res, 60, 5710-13.
  16. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T (2002). Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostate hyperplasia in Japanese. Urol Int, 68, 226-31. https://doi.org/10.1159/000058440
  17. Izmirli M, Arikan B, Bayazit Y, Alptekin D (2011). Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men. Asian Pac J Cancer Prev, 12, 731- 3.
  18. Karimpur-Zahmatkesh A, Farzaneh F, Pouresmaeili F et al (2013). A2 allele polymorphism of the CYP17 gene and prostate cancer risk in an Iranian population. Asian Pac J Cancer Prev, 14, 1049-52. https://doi.org/10.7314/APJCP.2013.14.2.1049
  19. Kehinde EO, Sheikh M, Mojimoniyi OA, et al (2003). High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma. BJU Int, 91, 618-22. https://doi.org/10.1046/j.1464-410X.2003.04199.x
  20. Konwar R, Chattopadhyay N, Bid HK (2008). Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int, 102, 536-44. https://doi.org/10.1111/j.1464-410X.2008.07667.x
  21. Li J, Coates RJ, Gwinn M, Khoury MJ, (2010). Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am J Epidemiol, 171, 1-13. https://doi.org/10.1093/aje/kwp318
  22. Madigan MP, Guo YT, Deng J, et al (2003). CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer, 107, 271-5. https://doi.org/10.1002/ijc.11378
  23. Manchanda PK, Konwar R, Nayak VL, Singh V, Bid HK (2010). Association of genetic variants of the vitamin D receptor (VDR) gene, (Fok-1, Taq-1 and Bsm-I) with susceptibility of benign prostate hyperplasia in a North Indian population. Asian Pac J Cancer Prev, 11, 1005-8.
  24. McConnell J, Abrams P, Denis L, Khoury S, Roehrborn C, eds (2006). Male Lower Urinary Tract Dysfunction: Evaluation and Management. Paris, France, Health Publ.
  25. Mullan RJ, Bergstralh EJ, Farmer AS, et al (2006). Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urol, 67, 300-05. https://doi.org/10.1016/j.urology.2005.08.061
  26. Oh JJ, Byun SS, Lee SE et al (2014). Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population. Gene, 533, 86-93. https://doi.org/10.1016/j.gene.2013.09.119
  27. Orsted DD, Bojesen SE (2013). The link between benign prostatic hyperplasia and prostate cancer, Nature Rev Urol, 10, 49-54.
  28. Pearson JD, Lei HH, Beaty TH, et al (2003). Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology, 61, 781-5. https://doi.org/10.1016/S0090-4295(02)02509-8
  29. Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E. (2000). Race, ethnicity and benign prostatic hyperplasia in the health professionals' follow-up study. J Urol, 163, 490-5. https://doi.org/10.1016/S0022-5347(05)67909-8
  30. Rajender S, Vijayalakshmi K, Pooja S et al (2009). Longer (TA) n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl, 30, 703-10 https://doi.org/10.2164/jandrol.108.007377
  31. Roberts RO, Bergstralh EJ, Farmer SA, et al (2006). Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia. Prostate, 66, 392-404. https://doi.org/10.1002/pros.20362
  32. Ruan L, Zhong WD, Li ZM, Hua X (2011). Relationship between vitamin D receptor gene Fok I polymorphisms and benign prostatic hyperplasia complicated by histological prostatitis. Zhonghua Nan Ke Xue, 17, 880-3.
  33. Salam MT, Ursin G, Skinner EG, Dessissa T, Reichardt JK (2005). Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol, 23, 246-53. https://doi.org/10.1016/j.urolonc.2004.12.014
  34. Schatzl G, Gsur A, Bernhofer G, et al (2001). Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urol, 57, 567-72. https://doi.org/10.1016/S0090-4295(00)01004-9
  35. Sobti RC, Gupta L, Thakur H (2009). CYP17 gene polymorphism and its association in north Indian prostate cancer patients. Anticancer Res, 29, 1659-63
  36. Tayeb MT, Clark C, Haites NE, et al. (2004). Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J, 25, 447- 51.
  37. Taylor JA, Hirvonen A, Watson M, et al (1996). Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res, 56, 4108-10.
  38. Tigli H, Yazici H, Dalay N (2003). CYP17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia," Res Commun Mol Pathol Pharmacol, 113-4, 307-14.
  39. Verhamme KM, Dielemana JP, Bleuminka GS, et al (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-The Triumph Project. Eur Urol, 42, 323-8. https://doi.org/10.1016/S0302-2838(02)00354-8

Cited by

  1. Promoter Polymorphism (rs12770170, -184C/T) of Microseminoprotein, Beta as a Risk Factor for Benign Prostatic Hyperplasia in Korean Population vol.18, pp.2, 2014, https://doi.org/10.5213/inj.2014.18.2.63
  2. Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5557
  3. Human Kallikrein-2, Prostate Specific Antigen and Free-Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7085
  4. SRD5A2 Gene Polymorphisms and the Risk of Benign Prostatic Hyperplasia but not Prostate Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1033
  5. Association between Single Nucleotide Polymorphism of Vitamin D Receptor Gene FokI Polymorphism and Clinical Progress of Benign Prostatic Hyperplasia vol.2015, pp.1537-744X, 2015, https://doi.org/10.1155/2015/235895
  6. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels vol.14, pp.11, 2017, https://doi.org/10.3390/ijerph14111318
  7. I) with prostate cancer: a new meta-analysis vol.45, pp.1, 2017, https://doi.org/10.1177/0300060516668939